[go: up one dir, main page]

BR9709077A - Compounds inhibiting matrix metalloproteinase composition having matrix metalloprotease inhibitory processes processes to inhibit matrix metalloprotease activity and to treat a mammal - Google Patents

Compounds inhibiting matrix metalloproteinase composition having matrix metalloprotease inhibitory processes processes to inhibit matrix metalloprotease activity and to treat a mammal

Info

Publication number
BR9709077A
BR9709077A BR9709077A BR9709077A BR9709077A BR 9709077 A BR9709077 A BR 9709077A BR 9709077 A BR9709077 A BR 9709077A BR 9709077 A BR9709077 A BR 9709077A BR 9709077 A BR9709077 A BR 9709077A
Authority
BR
Brazil
Prior art keywords
processes
matrix
matrix metalloprotease
mammal
treat
Prior art date
Application number
BR9709077A
Other languages
Portuguese (pt)
Inventor
Brian R Dixon
Jinshan Chen
Original Assignee
Bayer Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Ag filed Critical Bayer Ag
Publication of BR9709077A publication Critical patent/BR9709077A/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D209/00Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/44Iso-indoles; Hydrogenated iso-indoles
    • C07D209/48Iso-indoles; Hydrogenated iso-indoles with oxygen atoms in positions 1 and 3, e.g. phthalimide
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/02Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/02Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C229/34Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton containing six-membered aromatic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/40Unsaturated compounds
    • C07C59/76Unsaturated compounds containing keto groups
    • C07C59/90Unsaturated compounds containing keto groups containing singly bound oxygen-containing groups

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Steroid Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)
BR9709077A 1996-05-15 1997-05-12 Compounds inhibiting matrix metalloproteinase composition having matrix metalloprotease inhibitory processes processes to inhibit matrix metalloprotease activity and to treat a mammal BR9709077A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US64502896A 1996-05-15 1996-05-15
PCT/US1997/007921 WO1997043245A1 (en) 1996-05-15 1997-05-12 Inhibition of matrix metalloproteases by acetylene containing compounds

Publications (1)

Publication Number Publication Date
BR9709077A true BR9709077A (en) 1999-08-03

Family

ID=24587368

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9709077A BR9709077A (en) 1996-05-15 1997-05-12 Compounds inhibiting matrix metalloproteinase composition having matrix metalloprotease inhibitory processes processes to inhibit matrix metalloprotease activity and to treat a mammal

Country Status (18)

Country Link
EP (1) EP0912496A1 (en)
JP (1) JP3090957B2 (en)
CN (1) CN1139570C (en)
AR (1) AR007097A1 (en)
AU (1) AU710759B2 (en)
BR (1) BR9709077A (en)
CA (1) CA2253796C (en)
CO (1) CO5080759A1 (en)
HN (1) HN1997000088A (en)
HR (1) HRP970245B1 (en)
ID (1) ID16910A (en)
PA (1) PA8429301A1 (en)
SV (1) SV1997000035A (en)
TN (1) TNSN97084A1 (en)
TW (1) TW381079B (en)
WO (1) WO1997043245A1 (en)
YU (1) YU18697A (en)
ZA (1) ZA974031B (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6288063B1 (en) 1998-05-27 2001-09-11 Bayer Corporation Substituted 4-biarylbutyric and 5-biarylpentanoic acid derivatives as matrix metalloprotease inhibitors
AR035478A1 (en) * 1999-01-27 2004-06-02 Wyeth Corp AMIDA-HYDROXAMIC ACID, ACETYLLENE, BETA-SULPHONAMIDE AND PHOSPHINIC ACID AS INHIBITORS OF TACE, USE OF THE SAME FOR THE MANUFACTURE OF A MEDICINAL PRODUCT AND PHARMACEUTICAL COMPOSITION CONTAINING THEM
US6326516B1 (en) 1999-01-27 2001-12-04 American Cyanamid Company Acetylenic β-sulfonamido and phosphinic acid amide hydroxamic acid TACE inhibitors
EP1031349A1 (en) * 1999-02-25 2000-08-30 Bayer Aktiengesellschaft Use of substituted 4-biarylbutyric and 5-biarylpentanoic acid derivatives for the treatment of cerebral diseases
US7141607B1 (en) 2000-03-10 2006-11-28 Insite Vision Incorporated Methods and compositions for treating and inhibiting retinal neovascularization
HUE030114T2 (en) * 2010-07-08 2017-04-28 Kaken Pharma Co Ltd N-hydroxyformamide derivative and pharmaceutical containing same
JP2017509665A (en) 2014-04-03 2017-04-06 バイエル ファーマ アクチエンゲゼルシャフト 2,5-Disubstituted cyclopentanecarboxylic acids for the treatment of airway diseases
US20170022171A1 (en) 2014-04-03 2017-01-26 Bayer Pharma Aktiengesellschaft 2,5-disubstituted cyclopentanecarboxylic acids and their use
US20170119776A1 (en) 2014-04-03 2017-05-04 Bayer Pharma Aktiengesellschaft Chiral 2,5-disubstituted cyclopentanecarboxylic acid derivatives and use thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3784701A (en) * 1970-09-21 1974-01-08 American Cyanamid Co Compositions containing substituted benzoylpropionic acids and method of use to treat inflammation and pain
DE2112716A1 (en) * 1971-03-17 1972-10-05 Thomae Gmbh Dr K Biphenylyl-butyric acid derivs. - anti phlogistics
FR2378741A1 (en) 1977-02-01 1978-08-25 Fabre Sa Pierre GARYL GOXO ISOVALERIC ACIDS WITH ANTIPHLOGISTIC AND ANTALGIC PROPERTIES
US5789434A (en) 1994-11-15 1998-08-04 Bayer Corporation Derivatives of substituted 4-biarylbutyric acid as matrix metalloprotease inhibitors
ZA974033B (en) 1996-05-15 1998-02-19 Bayer Ag Substituted 4-arylbutyric acid derivatives as matrix metalloprotease inhibitors.

Also Published As

Publication number Publication date
ID16910A (en) 1997-11-20
JP3090957B2 (en) 2000-09-25
JPH11511179A (en) 1999-09-28
ZA974031B (en) 1998-02-19
CN1139570C (en) 2004-02-25
CO5080759A1 (en) 2001-09-25
HRP970245A2 (en) 1998-04-30
AU710759B2 (en) 1999-09-30
TNSN97084A1 (en) 2005-03-15
TW381079B (en) 2000-02-01
CA2253796A1 (en) 1997-11-20
WO1997043245A1 (en) 1997-11-20
CA2253796C (en) 2003-10-28
YU18697A (en) 1999-11-22
SV1997000035A (en) 1999-01-14
PA8429301A1 (en) 2000-05-24
HN1997000088A (en) 1997-06-18
CN1225623A (en) 1999-08-11
AU2938697A (en) 1997-12-05
HRP970245B1 (en) 2002-06-30
AR007097A1 (en) 1999-10-13
EP0912496A1 (en) 1999-05-06

Similar Documents

Publication Publication Date Title
AR009356A1 (en) COMPOUND OF 1-4 HETEROCICLICO, METALOPROTEASE INHIBITOR AND ITS USE TO PREPARE A PHARMACEUTICAL COMPOSITION AND TO PREVENT OR TREAT A DISEASE ASSOCIATED WITH METALO PROTEASE ACTIVITY AND CAQUEXIA
FI965156A7 (en) Arylsulfonamido-substituted hydroxamic acids as matrix metalloproteinase inhibitors
BR9509802A (en) Matrix metalloprotease inhibitors
BR9709086A (en) Matrix metalloproteinase inhibitors having matrix metalloprotease inhibitory processes Processes to inhibit matrix metalloprotease activity in a mammal and to treat a mammal
DE69506219D1 (en) HYDRAULICALLY ACTUATED VALVE ARRANGEMENT
ATE224364T1 (en) BETA-SULFONAMIDO HYDROXAMIC ACID AS A MATRIX METALLOPROTEINASE AND AS TACE INHIBITORS
FI962905L (en) Metalloproteinase inhibitors
ATE219058T1 (en) ALPHA-SUBSTITUTED ARYLSULPHONAMIDOHYDROXAMIC ACID AS TNF-ALPHA AND MATRIX METALLOPROTEINASE INHIBITORS
NO20002469D0 (en) Aromatic sulfonic hydroxamic acid metalloprotease inhibitor
DK0925022T3 (en) Improvements related to skin tingling needles
FI954351A7 (en) Hydroxamic acid derivatives as metalloproteinase inhibitors
TR199903287T2 (en) Matrix metalloproteinazlar�n�n ters hydroxamate inhibitors.
BR9711988A (en) Matrix metalloproteinase inhibitors and their therapeutic uses
DE69808518D1 (en) ACE HEMMER / MATRIX METALLOPROTEINASE HEMMER-DRUG COMBINATIONS
BR9709077A (en) Compounds inhibiting matrix metalloproteinase composition having matrix metalloprotease inhibitory processes processes to inhibit matrix metalloprotease activity and to treat a mammal
FI960482A7 (en) Matrix metalloprotease inhibitors
DE59705298D1 (en) SYSTEM FOR AUTOMATICALLY INPUTING AND REMOVING REELS
IL127262A0 (en) Matrix metalloproteinase inhibitors
FI972198A7 (en) Metalloproteinase inhibitors
HUP9904165A3 (en) 3-mercaptoacetylamino-1,5-substituted-2-oxo-azepan derivatives useful as inhibitors of matrix metalloproteinase and use thereof
BR9709084A (en) Matrix metalloproteinase inhibition composition having matrix metalloprotease inhibiting activity and processes for inhibiting matrix metalloprotease activity in a mammal and for treating mammals
DE69819206D1 (en) matrix metalloproteinase
BR9607384A (en) Hydraulic lift valve
NO996234L (en) Spray formulations of antihyperalgesic opiates and methods for treating topical hyperalgesic conditions and itching therewith
BR9709075A (en) Compounds having matrix metalloprotease inhibiting activity

Legal Events

Date Code Title Description
FB36 Technical and formal requirements: requirement - article 36 of industrial property law
B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements